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Summary 57 primary tumour samples from Indian oral cancer patients with a 5-15 year tobacco chewing
habit, were examined for mutational activation in codons 12, 13 and 61 of the H-ras, K-ras and N-ras
oncogenes. The highly sensitive assay based on specific oligonucleotide hybridisation following in vitro
amplification of unique sequences by polymerase chain reaction was employed. Mutations were detected in
twenty (35%) of the samples and were restricted to H-ras, codons 12, 13 and 61. Two cases had concurrent
mutations in codons 12 and 61. The majority of the mutations were at H-ras 61.2 (Glutamine to Arginine) and
H-ras 12.2 (Glycine to Valine). Three of the less frequent mutations are apparently novel. Interestingly, eight
of the samples with H-ras mutations also showed loss of wild-type H-ras, as judged by absence of signals for
wild-type codons 12 or 61 on dot blots. The specific H-ras mutations in these oral malignancies associated
with tobacco chewing, may represent an important example of an environmental carcinogen-induced step, in a
pathway leading to malignant transformation.
Squamous cell carcinoma (SCC) of the oral cavity are a
major cause of mortality in several developing countries,
comprising 40-50% of all malignancies in parts of India and
South East Asia (Pindborg, 1977; Sanghavi, 1981; Daftary,
1990). This high prevalence is in contrast to 2-4% of the
total malignancies in the developed Western countries (Bin-
nie, 1976; Field & Spandidos, 1987). In India, there is an
unequivocal relationship between chewing tobacco and oral
cancer (Daftary, 1990; Gupta et al., 1987; Jussawalla &
Deshpande, 1971). Oral malignancies in developed Western
countries are also associated with tobacco, used either in
cigarettes (Wynder & Stellman, 1977); or as moist snuff
placed between the cheek and gum (Winn, 1984). In general,
most tobacco-related oral malignancies in India are preceded
by a clinically distinctive premalignant stage such as leuko-
plakia (Daftary, 1990). Oral SCCs in developed countries
may be, but usually are not, preceded by the appearance of
premalignant lesions (Binnie, 1990).
Recently, several oncogenes previously shown to be
involved in various human malignancies (Klein & Klein,
1985; Yokota et al., 1986), have been implicated in oral
cancers (Field & Spandidos, 1987; Hoellering & Shuler, 1988;
Saranath et al., 1989; Saranath et al., 1990). In the Indian
cases of oral SCCs examined by Saranath and co-workers
(1989), a 5- to 10-fold amplification of one or more of the
c-myc, N-myc, K-ras and N-ras oncogenes was observed in
13/23 (56%) of the tumour samples. Multiple oncogene
amplification was correlated with advanced disease stages III
and IV. Neither L-myc nor H-ras were amplified in the
SCCs. Further, studies on restriction fragment length
polymorphism (RFLP) with respect to L-myc in oral cancer
patients demonstrated the S allele (6.6kb EcoRI fragment)
predominating in poor to moderately differentiated tumours,
as well as larger sized tumours (Saranath et al., 1990).
Mutations leading to the activation of cellular ras proto-
oncogenes have been identified in several human malignan-
cies of diverse origin (Bos, 1989). The family of ras genes
includes three well characterised genes, H-ras, K-ras and
N-ras, encoding 21 kDa proteins that bind guanine nucleo-
tides, possess GTPase activity and are localised at the inner
surface of the plasma membrane (Barbacid, 1987). In vivo
mutations in ras genes have been restricted to codons 12, 13
and 61, although in vitro mutations in several other codons
have transforming activities (Bos, 1989).
Saiki et al. (1985) were the first to describe the use of
synthetic oligonucleotide probes to detect and identify point
mutations in DNA enzymatically amplified in vitro by the
polymerase chain reaction (PCR) technique. PCR has been
used in several studies identifying ras mutations in human
malignancies. In this study we have used the PCR technique
and specific oligonucleotide probe to investigate the presence
of point mutations in ras genes in Indian cases of chewing-
tobacco-associated oral SCCs. We demonstrate a high fre-
quency (35%) of ras mutations, with these being restricted to
H-ras gene, at codons 12, 13 and 61. No mutations in codons
12, 13 or 61 of K-ras or N-ras were detected in the 57
primary oral tumour samples screened.
Materials and methods
Patients
Fifty-seven untreated patients (47 males and ten females,
aged between 28 and 65 years), diagnosed as having
squamous cell carcinoma of the oral cavity and with TNM
stages (UICC 1988), T2 to T4, No to N3 and Mo, were
investigated for ras mutations. The diagnosis was based on
clinical examination and histological features of the biopsy
material. The various sites included buccal mucosa - 27
cases, lower alveolus - 17 cases, tongue - 11 cases, and floor
of the mouth - two cases, with either poor, moderate or well
differentiated carcinoma.
Tumour tissues
For the present studies tissue was taken from resections of
primary tumours near the advancing edges, care being taken
to avoid the necrotic centre. Tissue specimens were minced,
washed extensively in 0.1 M phosphate buffered saline
(pH 7.2), homogenised and stored in liquid nitrogen, until
isolation of DNA. The samples were serially coded irrespec-
tive of the clinico-pathological status of the patients.
DNA extraction
DNA was extracted from the carcinoma samples, according
to the standard method of Maniatis et al. (1982).
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Polymerase chain reaction
Selective regions of the sample DNAs around codons 12, 13
and 61 of each ras gene were amplified in vitro using the
PCR technique (Saiki et al., 1985), and conditions recom-
mended by Perkin Elmer Cetus for their Thermocycler. Each
PCR reaction in a total volume of 100 gl, contained 1l g
genomic DNA, 10 mM Tris (pH 7.5), 50 mM NaCl, 10 mM
MgCl2, 1.5 mM of each dNTP and 1 1tmol of each primer
(two ofeach reaction). The tubes were held at 94°C for 5 min
and then cooled to 55°C before addition of 1 unit of Taq
polymerase (Cetus). For H-ras the pairs of primers used in
the PCR reactions are described in Figure 1, with amplified
sequences of llbp and 178 bp for the regions flanking
codons 12, 13 and 61 respectively. The samples were sub-
jected to 30 cycles of PCR amplification using the Thermo-
cycler. Denaturation was at 94°C, annealing at 42°C and
extension at 70°C. The PCR reactions were routinely checked
for amplified DNA on agarose gels.
a Exon 1
P1
Exon II
P3
H- 12/13 H- 6
-~~~~~~~~~F-
P2 P4
l (I1I1 bp) (178 bp)
b H-RAS Exon
P 1 (1-21) ATGACGGAATATAAGCTGGTG
P 2 (90-111) CTCTATAGTGGGGTCGTATTC
Exon II
P 3 (112-133) GATTCCTACCGGAAGCAGGTG
P 4 (269-290) CTGTACTGGTGGATGTCCTCA
sense
anti-sense
sense
anti-sense
Figure 1 Primers utilised in amplification of the H-ras codons
12, 13 and 61, and the fragment sizes of the amplified sequences.
Oligonucleotide probe hybridisation
Five glI (50 ng) aliquots of the amplified DNA was denatured
by addition of an equal portion of 800 mM NaOH/50 mM
EDTA and spotted onto Gene Screen filters (Dupont) with a
BioRad dot-blot apparatus. Replicate filters were prepared
and the DNA fixed by UV illumination. The filters were
prehybridised for 2-4 h at 48°C in a buffer containing
6 x SSPE (1 x SSPE = 10 mM sodium phosphate (pH 7.2)/
0.18 M NaCI/l mM EDTA), 6 x Denhardt's (1 x Denhardt's
solution = 0.02% Ficoll/0.02% Polyvinylpyrrolidone/0.02%
bovine serum albumin) and 1% Sodium dodecyl sulphate
(SDS). The filters for H-ras 61 probes were prehybridised
overnight at 58°C in a buffer containing 5 x SSPE, 0.3%
SDS and 200 ig ml1' denatured salmon sperm DNA.
Hybridisation of the filters with the oligonucleotide probes
was carried out overnight. The oligoprobes (20 mers) were
5'-end labelled by phosphorylation with 20 gLCi ('y32P) ATP
(Amersham, specific activity 5,000 mCi mmol-') and T4
polynucleotide kinase (Bethesda Research Laboratory).
Washing of the filters, except those for H-ras codon 61, was
carried out in 3 M tetramethylammonium chloride (Fluka)
containing 50 mM Tris (pH 8.6), 2 mM EDTA and 0.1% SDS
at 63°C for 20 min. The H-ras codon 61 filters were washed
at 67°C for 20 min in 5 x SSC containing 0.1% SDS. The
filters were exposed to Fuji X-ray films at - 70°C using
intensifying screens, for a period of 1-15 h.
Initial screening of the amplified DNA utilised mixed
probes, each set covering one nucleotide position of a partic-
ular codon. On indication of a mutation, a duplicate PCR of
the genomic DNA was performed, and the two independ-
ently amplified DNAs were then screened simultaneously
with a set of single oligonucleotide probes specific for the
nucleotide position. The presence of wild-type codons were
screened for, in every set of blots. Table I lists the sequence
of our H-ras probes. All custom primers and probes were
synthesised at the Imperial Cancer Research Fund. Their
sequences are available on request.
Results
Fifty-seven DNA samples were screened for the presence of
point mutations in codons 12, 13 and 61 of the ras
oncogenes. Of these samples 20 contained ras mutations
(Tables II and III, Figure 2). All these mutations were
restricted to H-ras, with eight samples mutated at codon 12,
one at codon 13 and thirteen at codon 61. None of the
samples showed mutations in codons 12, 13 or 61 of K-ras or
N-ras. Two of the samples (17BM and 33LA) showed con-
current H-ras mutations at codons 12 and 61. Thus, 35%
(20/57) of the oral SCC samples showed point mutations in
the H-ras gene. Correlation between the presence of H-ras
mutations and tumour size, nodal status or stage of
differentiation of the oral SCC was not observed (Table III).
The common amino acid substitutions were glycine to
valine (G to T transversion) at codon 12.2 (seven samples),
and glutamine to arginine (A to G transition) at codon 61.2
(ten samples). Three cases showed a glutamine to histidine (G
to T transversion) change at codon 61.3. There was one case
each of glycine to serine (G to A transition) at codon 12.1,
glycine to aspartate (G to A transition) at codon 13.2, and
glutamine to leucine (A to T transversion) at codon 61.2. The
mutations demonstrated an equal number, eleven cases each,
of nucleotide transitions and transversions.
Of the observed H-ras mutations, three types are appar-
ently novel. These include the G to A (glycine to serine)
substitution at codon 12.1, the G to A (glycine to aspartate)
substitution at codon 13.2, and the G to T (glutamine to
histidine) substitution (three cases) at codon 61.3, 6/7 sam-
ples showing a glycine to valine substitution at codon 12.2,
and 2/10 samples with a glutamine to arginine substitution at
codon 61.2, demonstrated loss of the wild-type codon 12.2
and 61.2 respectively, as judged by the absence of signals on
the dot blots (Figure 2).
Table I Probes used to identify point mutations in H-ras
Probe Sequence (Complementary to coding strand)
H 12 WT TT GCC CAC ACC GCC GGC GCC
H 12 P1 GCN N=A,G,T
H 12 P2 GNC N=A,G,T
H 13 WT TT GCC CAC ACC GCC GGC GCC
H 13 P1 ACN N=A,G,T
H 13 P2 ANC N=A,G,T
H 61 WT TA CTC CTC CTG GCC GGC GGT
H 61 P1 CTN N=A,C,T
H 61 P2 CNG N = A,C,G
H 61P3 NTG N=A,G
WT = Wild type, P = Position.H-RAS POINT MUTATIONS IN HUMAN ORAL CANCERS 575
Table II H-ras mutations in SCC of the oral cavity
H-ras mutations
Alterations
Amino
Nucleotide acid
GGC->GTC Gly+Val
GGC+GTC Gly+Val
GGC+GTC Gly+Val
GGC+GTC Gly+Val
GGC+GTC Gly+Val
GGC+GTC Gly+Val
GGC+GTC Gly+Val
GGC+AGC Gly+Ser
GGC-*GAC Gly-*Asp
CAG+CGG Gln+Arg
CAG+CGG Gln+Arg
CAG+CGG Gln+Arg
CAG->CTG Gln+Leu
CAG+CGG Gln+Arg
CAG+CGG Gln+Arg
CAG+CGG Gln+Arg
CAG+CGG Gln+Arg
CAG+CAT Gln+His
CAG->CAT Gln+His
CAG+CAT Gln+His
CAG-*CGG Gln+Arg
CAG+CGG Gln-*Arg
Amplification
of oncogenes**
N-ras; H-ras****
Allelic loss (RFLP)
K-ras
N-myc
c-myc, N-myc,
N-ras
N-myc, N-ras
N-myc, K-ras,
N-ras
N-myc, K-ras,
N-ras
K-ras
alveolus differentiated
*Wild type gene present (+) or absent (-), as detected on dot blots in hybridisation with specific single oligonucleotide probe. **Extended
studies on reported data - Saranath et al., 1989. ***Sample Nos. 17BM and 33LA contained two mutations each. ****Deletion of 7.4 kb
BamHI fragment of H-ras allele (Saranath et al., Ms. Sub. Int. J. Cancer).
Table III Summary of total oral cancer patients screened for mutated ras
genes
H-ras 12/61 Normal
TNM Total cases mutation H-ras x2t
staging* (57) (20) (37) 1 df.
Tumour size
Tx/Tl 1 I
T2 11 7 4 3.606NS
T3 3 - 3
T4 42 13 29
Nodal status
NO 24 6 18
NI 18 10 8 0.025NS
N2 15 4 11
Degree of differentiation
Well 22 8 14
Moderate 30 8 22 3.23NS
Poor 5 4 1
*UICC, 1988. tNS - Non significant.
Discussion nucleotide probe hybridisation analysis to detect point muta-
tions in ras genes, in chewing-tobacco-related oral malignan-
We have used the sensitive technique of in vitro enzymatic cies in India. Our results indicate that a significantly high
amplification of target DNA sequences followed by oligo- proportion of oral cancer patients i.e. 20/57 (35%) contain
Wild
t)
ge Patient nos.
17 BM***
28 BM
32 LA
33 LA***
44 LA
45 LA
58 FM
20 BM
26 BM
21 BM
25 BM
40 LA
42 LA
47 T
50 T
51 T
57 FM
36 LA
43 LA
48 T
17 BM***
33 LA***
DNA
source
Buccal
mucosa
Buccal
mucosa
Lower
alveolus
Lower
alveolus
Lower
alveolus
Lower
alveolus
Floor of
mouth
Buccal
mucosa
Buccal
mucosa
Buccal
mucosa
Buccal
mucosa
Lower
alveolus
Lower
alveolus
Tongue
Tongue
Tongue
Floor of
mouth
Lower
alveolus
Lower
alveolus
Tongue
Buccal
mucosa
Lower
Histological
diagnosis
Poorly
differentiated
Well
differentiated
Poorly
differentiated
Poorly
differentiated
Well
differentiated
Well
differentiated
Moderately
differentiated
Well
differentiated
Well
differentiated
Well
differentiated
Well
differentiated
Moderately
differentiated
Moderately
differentiated
Poorly
differentiated
Moderately
differentiated
Moderately
differentiated
Moderately
differentiated
Moderately
differentiated
Well
differentiated
Moderately
differentiated
Moderately
differentiated
Poorly
Age-yr
(sex)
40 (M)
45 (M)
48 (M)
50 (M)
45 (M)
33 (M)
35(M)
40 (F)
60 (M)
50 (F)
55 (F)
35 (F)
45 (M)
45 (M)
40 (M)
50 (M)
65 (M)
44 (M)
45 (F)
35 (M)
40 (M)
50 (M)
TNM
staging
T2N1Mo
T4NOMO
T4NIMo
T4N1Mo
T4N2Mo
T4NoMo
T2NoMo
T2N1Mo
T4N1Mo
T2N,Mo
T4NIMO
T4N2Mo
T4N1Mo
T2NoMo
T2NOMO
T4N2Mo
T4N2M0
T4N,Mo
T4NoMo
T2N,Mo
T4N1Mo
T4NJMo
ype Codon
ene* position
- 12.2
- 12.2
- 12.2
+ 12.2
- 12.2
- 12.2
- 12.2
+ 12.1
+ 13.2
+ 61.2
+ 61.2
- 61.2
+ 61.2
+ 61.2
- 61.2
+ 61.2
+ 61.2
+ 61.3
+ 61.3
+ 61.3
+ 61.2
+ 61.2576 D. SARANATH et al.
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a .. ...
LA
Probe
>IHIRAS Codon 12
Wt: Glycine
-GCC-
Alanine
-GAC-
Aspartate
-GTC-
Valine
:- .-
Probe
K. RAS Codon 61
-CiG-
Wt: Glutemine
L.eucine
~-CG.G-
Arginine
Proline
c
Pmbe
RHAS C on 61
-CAG-
Glutamine
-CAT-:
Hlstidtne
-CAC-
HistidOne
Figure 2 Characterisation of point mutations in codons 12 and 61 of H-ras gene. The panels show two independently amplified
samples from the same patient, on hybridisation of the dot blots to different oligonucleotide probes. a, Shows the H-ras codon 12
base 2 wild type missing in samples 17 BM, 28 BM, 32 LA, 44 LA and 58 FM; and GGC (glycine) mutated to GTC (valine) in the
six samples mentioned above, with an additional mutated sample 33 LA showing the wild type present. Samples 3 BM, 15 BM,
9 BM, 26 BM, 29 LA, 46 T, 31 LA and 57 FM do not contain point mutations in H-ras codon 12.2. There were no mutations to
cause Glycine to Alanine or asparatate substitutions, b, shows wild type H-ras codon 61 base 2 missing in two samples 40 LA and
50 T; and the CAG (Glutamine) mutated to CTG (Leucine) in sample 42 LA, CAG mutated to CGG (Arginine) in the nine
samples labelled in the figure. No mutations were observed to cause a Glutamine to Proline substitution, c, shows the H-ras codon
61 base 3 wild type (top panel) with CAG (Glutamine) codons. Sample numbers 36 LA, 43 LA and 48 T show mutations to CAT
(Histidine) with no other samples mutated at this position.
bH-RAS POINT MUTATIONS IN HUMAN ORAL CANCERS 577
point mutations in codons 12, 13 or 61 of the H-ras gene.
Further, the mutations were restricted to H-ras, with none of
the 57 samples showing mutations in codons 12, 13 and 61 of
the K-ras and N-ras oncogenes. The point mutations were
predominantly in H-ras codon 61.2 (10/20), corresponding to
a glutamine to arginine substitution, and codon 12.2 (7/20)
corresponding to a glycine to valine substitution. Two of the
samples (17BM and 33LA) were unique in carrying both the
commonly occurring H-ras 61.2 and 12.2 mutations de-
scribed. It is not known whether the pair of mutations in
these two samples exist on a common H-ras allele or arose
from two distinct clonal populations.
In eight of the 20 cases with point mutations, an apparent
absence of the wild-type H-ras allele was observed, indicating
a deletion or loss of the normal H-ras allele, with or without
duplication of the mutated H-ras gene. In patient 28BM,
RFLP studies indicated loss of one H-ras allele (Table II;
Saranath et al., data unpublished). However, in patient
17BM, where both a H-ras 12.2 and 61.2 mutation were
observed, there was no signal for a wild-type H-ras codon 12
on the dot blots (Figure 2), whilst there was a positive signal
for a wild-type H-ras 61 codon (Figure 2). In this patient, the
12.2 mutation may exist in both alleles, whilst the 61.2
mutation was observed in only one allele. Loss of normal
H-ras allele with the presence of a mutated H-ras gene has
been reported in the EJ bladder carcinoma cell line
(Taparowsky et al., 1982).
Mutational activation of ras genes has been detected in a
wide variety of human neoplasms including solid epithelial
tissue and haematological malignancies (Bos, 1989; Bos et al.,
1987). Ras mutations have been shown to occur at a fre-
quency between 5 and 15% (Varmus, 1984; Pierce et al.,
1986). However, a higher frequency of 25 to 50% has also
been reported (Bos et al., 1985; Needleman et al., 1986; Farr
et al., 1988; Forrestor et al., 1987; Lemoine et al., 1989). In
several human cancers with ras mutations, a bias for muta-
tions to occur in a particular member of the ras family is
noted. For example, H-ras mutations predominate in human
bladder carcinoma (Fujita et al., 1985), whilst K-ras muta-
tions frequently occur in lung and colon carcinomas (Bos et
al., 1987; Forrestor et al., 1987) and N-ras mutations are
particularly associated with haematological malignancies
(Bos et al., 1985; Needleman et al., 1986; Janssen et al.,
1987). However, the association between the malignancy and
the particular member of the ras family is generally not
exclusive, with few exceptions, such as pancreatic cancer and
K-ras reviewed by Bos (1989). Thus, the detection of only
H-ras mutations in chewing-tobacco-related oral SCCs
appears to be unique, and the high prevalence - 35%
amongst the 57 cases examined, is exceptional.
Previous work by some of us (Saranath et al., 1989) has
shown that over 50% of chewing-tobacco-related oral SCCs
in India have a 5- to 10-fold DNA amplification of one or
more of the c-myc, N-myc, K-ras and N-ras oncogenes, but
no amplification of H-ras or L-myc. The question ofmyc and
ras amplifications in the 57 cases presented in this study has
also been investigated (unpublished data). A summary of this
DNA amplification data is presented in Table II, indicating
ras activation in Indian oral SCCs by both amplification as
observed in K-ras and N-ras, and point mutations observed
in H-ras.
The absence of either a normal H-ras codon 12 or 61
signal in 8/20 (40%) of the H-ras mutation positive samples
on the dot blots is noteworthy. The inactivation or loss of
normal H-ras alleles may be important in tumour progres-
sion, as demonstrated in colorectal (Baker et at., 1989) and
breast carcinoma (Theillet et at., l1986). The apparent loss of
the wild-type H-ras allele on chromosome 11, may be signifi-
cant, not only for the loss of the H-ras gene itself, but for the
loss or effective neutralisation of a nearby regulatory or
tumour suppressor gene (Saxon et al., 1986). Loss of H-ras
allele has been reported in one offive oral SCC (in Canadian
patients) by Howell and colleagues (Howell et al., 1989).
A crucial question is at what stage of oral cancer develop-
ment or progression do the H-ras mutations occur? It may be
significant that seven of the 20 samples with H-ras mutations
occur in stage II tumours, in contrast to myc and ras
amplifications which generally accompany stage III and IV
malignancies (Saranath et al., 1989). Possibly H-ras muta-
tions are important at an earlier stage of oral SCC develop-
ment, with the myc and ras amplifications associated with the
advanced stages (Saranath et al., 1989). However, 12 of the
20 samples with activated ras contain a normal H-ras gene,
and eight of these are T4. Thus, loss of the normal H-ras
allele in these tumours containing one mutated H-ras allele is
not necessary for progression to the T4 stage.
The oral cancer patients in this study were habitual
tobacco chewers (5 to 15 years) and developed carcinomas at
the site where the tobacco folded in 'quid' was kept for
prolonged periods. Nitroso-containing compounds also pre-
sent in tobacco, are known to induce H-ras mutations in
experimental animals (Zarbl et al., 1985; Quintanilla et al.,
1986). Our data strongly suggest that particular carcin-
ogen(s), probably of nitroso origin, in tobacco, can affect
specific base mutations at codons 12, 13 and 61 of H-ras,
leading to oral malignancies. Different carcinogens present in
tobacco, may be responsible for the two major types of
mutations at H-ras 12.2 and 61.2, observed in our primary
oral tumours. An equal number of transitions and transver-
sions were found amongst our H-ras mutations. In general
nitrosamines preferentially (but not exclusively) produce tran-
sitions whilst other carcinogens, like benzo(a)pyrene, cause
transversions.
Preliminary studies of oral SCC from patients resident in
the United Kingdom shows that H-ras mutations infre-
quently occur among such cancers (Chang et al., unpub-
lished). Mutations in codons 12, 13 and 61 of H-ras, K-ras
and N-ras in these UK samples is a rare event. A possible
reason, for the difference in ras mutations frequency between
UK and Indian tobacco-associated oral malignancies may be
due to the mode of tobacco usage, the strains/species of
tobacco used and the curing process in the two countries.
In summary, our data demonstrate that a major step by
which chewing tobacco may cause oral malignancies is via
carcinogen effected point mutations at codons 12, 13 and 61
of H-ras. This activation may occur at a relatively early stage
in oral carcinogenesis. Further, inactivation or loss of the
normal H-ras allele, may provide a selective advantage to the
transformed clones. Since H-ras mutations may be bio-
logically important at an early stage of oral carcinogenesis,
such studies in premalignant lesions like leukoplakia are
currently in progress in our laboratories. A correlation
between the presence of H-ras mutations in premalignant
lesions and malignant transformation, would further indicate
the critical role of H-ras activation in oral carcinogenesis,
and perhaps predisposition of these lesions towards oral
malignancy.
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